SCHEMBL14854815

SCHEMBL14854815

CCN(CC)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OC1CCOC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.80
▸ ERBB2 P04626 11/20 0.80
▸ GAK O14976 3/20 0.69
▸ ABL1 P00519 3/20 0.69
▸ LCK P06239 3/20 0.69
▸ MET P08581 3/20 0.69
▸ PHKG2 P15735 3/20 0.69
▸ BLK P51451 3/20 0.69
▸ ERBB4 Q15303 3/20 0.69
▸ EPHA6 Q9UF33 3/20 0.69
▸ CIT O14578 2/20 0.69
▸ STK10 O94804 2/20 0.69
▸ LYN P07948 2/20 0.69
▸ HCK P08631 2/20 0.69
▸ SRC P12931 2/20 0.69
▸ AXL P30530 2/20 0.69
▸ FLT3 P36888 2/20 0.69
▸ TXK P42681 2/20 0.69
▸ FRK P42685 2/20 0.69
▸ CSNK1E P49674 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14854813 1.00 EGFR (0.80) EGFRERBB2GAKABL1LCK
SCHEMBL14854817 1.00 EGFR (0.80) EGFRERBB2GAKABL1LCK
SCHEMBL14854816 1.00 EGFR (0.80) EGFRERBB2GAKABL1LCK
SCHEMBL14854648 0.94 EGFR (0.78) EGFRERBB2GAKABL1LCK
SCHEMBL14854644 0.94 EGFR (0.78) EGFRERBB2GAKABL1LCK
SCHEMBL14854646 0.94 EGFR (0.78) EGFRERBB2GAKABL1LCK
SCHEMBL14854643 0.94 EGFR (0.78) EGFRERBB2GAKABL1LCK
SCHEMBL14864917 0.94 EGFR (0.70) EGFRERBB2GAKABL1LCK
SCHEMBL21573267 0.94 EGFR (0.70) EGFRERBB2GAKABL1LCK
SCHEMBL15222035 0.94 EGFR (0.71) EGFRERBB2GAKABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 — — EP claimed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 — — US claimed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 — — EP claimed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 — — US claimed
US-9676724-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 — — US claimed
EP-2581372-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2017-06-07 — — EP claimed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 — — US claimed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 — — US claimed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 — — US claimed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 — — EP claimed
CN-102933578-A Cyanoquinoline derivatives TIANJIN HEMAY BIO TECH CO LTD 2013-02-13 — — CN claimed
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 — — EP disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 — — US disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 — — EP disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 — — US disclosed
EP-2581372-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2017-06-07 — — EP disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 — — US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 — — US disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 — — EP disclosed
CN-102933578-A Cyanoquinoline derivatives TIANJIN HEMAY BIO TECH CO LTD 2013-02-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246443-B2 Cyanoquinoline derivatives CBR3, CYP3A4, CDK1 EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback